|
 |
NamendaThis page contains recent news articles, when available, and an overview of Namenda but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Namenda (when available) Memantine is an orally active NMDA receptor antagonist indicated for the treatment of moderate to severe dementia of the Alzheimer's type. Persistent activation of central nervous system N-methyl-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer's disease. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels. There is no evidence that Memantine prevents or slows neurodegeneration in patients with Alzheimer's disease. For the treatment of moderate to severe dementia of the Alzheimer's type. Mechanism Of Action: Memantine exerts its action through uncompetitive NMDA receptor antagonism, binding preferentially to the NMDA receptor-operated cation channels. Prolonged increased levels of glutamate in the brain of demented patients are sufficient to counter the voltage-dependent block of NMDA receptors by Mg2+ ions and allow continuous influx of Ca2+ ions into cells and ultimately neuronal degeneration. Studies suggest that memantine binds more effectively than Mg2+ ions at the NMDA receptor, and thereby effectively blocks this prolonged influx of Ca2+ ions through the NMDA channel whilst preserving the transient physiological activation of the channels by higher concentrations of synaptically released glutamate. Thus memantine protects against chronically elevated concentrations of glutamate. News Articles on Memantine New Data Highlight Positive Results of Namenda(R) (memantine HCl ... - Jul 30, 2008 ...presented today positive Phase III data of a once-daily extended-release formulation of Namenda(R) (memantine HCl) at the 2008 Alzheimer's Association MarketWatch Forest Laboratories announces positive Phase III data for ... - Aug 1, 2008 The study evaluated the efficacy, safety and tolerability of an innovative, proprietary, 28mg once-daily extended-release formulation of Namenda (memantine Trading Markets (press release), Forest Laboratories Announces Positive Phase III Data Of ... - Jul 30, 2008 The study evaluated the efficacy, safety and tolerability of Namenda, compared to placebo in outpatients with moderate to severe Alzheimer's disease RTT News, Earnings Preview: Forest Laboratories - Jul 21, 2008 Sales of Namenda, an NMDA receptor antagonist for the treatment of moderate and severe Alzheimer's disease, totaled $226M in the quarter, an increase of 26% Seeking Alpha, Forest Labs quarterly profit beats estimates - Jul 22, 2008 Sales of its Namenda Alzheimer's disease drug rose 14 percent to $218.6 million. Selling, general and administrative expenses increased 31.2 percent to $343 Reuters Examining Elan's Ups and Downs - Jul 31, 2008 Even though multiple compounds are already approved to alleviate Alzheimer's disease, like Aricept from Pfizer (NYSE: PFE), Namenda from Forest Labs (NYSE: Motley Fool Wyeth, Elan Alzheimer's Drug Tarnished by Side Effect in Study - Jul 29, 2008 About 95 percent of the patients in the study took another drug as well, such as Pfizer's Aricept or Forest Laboratories Inc.'s Namenda, Black said. Bloomberg Study: Exercise slows Alzheimer's brain atrophy - Jul 27, 2008 The Alzheimer's treatment market is small, led by Pfizer Inc.'s Aricept, Forest Laboratories Inc.'s Namenda, Razadyne from Johnson & Johnson and Shire Ltd., The Associated Press Alzheimer's Top Ten Care Recommendations - Aug 2, 2008 Ask the doctor about the medications: Aricept, Exelon, Razadyne and Namenda, which can mask and slow down dementia symptoms, keeping a person in the early HealthCentral.com, Forest 1Q profit falls 9 percent on Azor charge - Jul 22, 2008 Sales of Forest's top-selling drug, the antidepressant Lexapro, rose 6 percent to $583.1 million, while revenue from its Alzheimer's disease drug Namenda CNNMoney.com Researchers Say Medivation Alzheimer's Drug Dimebon Keeps Symptoms ... - Jul 30, 2008 Forest Laboratories Inc.'s (NYSE: FRX | Quote | Chart | News | PowerRating) Namenda, Novartis AG's (NYSE: NVS | Quote | Chart | News | PowerRating) Trading Markets (press release), Health briefs for week of July 15 - Jul 14, 2008 FAU’s Clinical Research Group is conducting a study to determine if Namenda, an FDA-approved medication, can help preserve the driving abilities of patients TCPalm, New Alzheimer's Drug Shows Promise - Jul 30, 2008 Daly currently takes Namenda and Aricept - two of the five FDA-approved drugs for Alzheimer's. But they only treat the symptoms, not the root cause of the CBS News, Alzheimer’s Research Brings Progress, Setbacks - Jul 18, 2008 ..."This drug could potentially add to the effects of other drugs such as Aricept, Namenda and Exelon," he said. "I think it's a pretty exciting development. Atlanta Journal Constitution, Ø£Øمد صبري: عدد مرضى الزهايمر سيكون مئة مليون عام 2050 - Jul 23, 2008 ليس بغرض الشÙ?اء كما اكدنا من قبل, بل يمكن ان ÙŠØµØ¨Ø Ø§Ù„Ù…Ø±ÙŠØ¶ من خلال تناول هذا العقار قادرا على الذهاب بمÙ?رده الى الØمام وهو عقار: »Namenda«. السياسة - العراق, Estudios muestran resultados mixtos en lucha contra el Alzheimer - Jul 18, 2008 ...entre los que se destacan Aricept de Eisai y Pfizer, Namenda de Forest Laboratories, Exelon de Novartis y Razadyne de Johnson & Johnson. Buena Salud å…»è€?院精神病è?¯æ»¥ç”¨å?±æƒ… - Jul 10, 2008 ...一些专家表示，还有一些è?¯ç‰©ï¼ˆå¦‚Ariceptã€?Exelonå’ŒNamenda 糖酒快讯网, Alzheimer's Drug May Prevent Brain Damage in Preemies - Jun 30, 2008 Scientists at Children's Hospital Boston in a study published in The Journal of Neuroscience say they used memantine (brand name Namenda) to stop Scientific American Alzheimer's Drug May Reduce Preemie Brain Injury - Jun 24, 2008 TUESDAY, June 24 (HealthDay News) -- The Alzheimer's drug memantine (brand name Namenda) may help reduce a form of brain injury that affects many premature Washington Post, Alzheimer’s Drug May Help Preemies - Jun 24, 2008 A new study suggests that Namenda, a drug originally developed to treat Alzheimer's disease, may help break the cycle of brain damage many premature infants WebMD Biotech Watch: Elan's Alzheimer's Drug Data - Jun 13, 2008 Aricept, a drug sold by Pfizer PFE and Eisai, and Namenda, sold by Forest Labs FRX, are the best selling of the bunch. So, Elan and Wyeth are trying to TheStreet.com Generics Embarking on Forest - Jun 13, 2008 Namenda will face generic competition by 2013, at the latest this puts another $1+ billion at risk. However, given the relatively cheap valuation (10.6x Trading Markets (press release), Forest Embarrassed Investors Who May Still Be Right (Update2) - Jun 19, 2008 Lexapro and Forest's Alzheimer's medicine, Namenda, generated $3.12 billion last year, 84 percent of the company's revenue. Looming patent expirations for Bloomberg Analyst Comments: Oxford, Telecom Argentina, Sonic Automotive, Web ... - Jun 12, 2008 Namenda will face generic competition by 2013, at the latest this puts another $1+ billion at risk. However, given the relatively cheap valuation (10.6x istockAnalyst.com, Analyst awaits data on Wyeth-Elan Alzheimer's drug - Jun 16, 2008 The Alzheimer's treatment market is led by four drugs: Pfizer Inc.'s Aricept, Forest Laboratories Inc.'s Namenda, Razadyne from Johnson & Johnson and Shire CNNMoney.com Sedating the Demented - Jun 25, 2008 As an aside, they mention used other anti-dementia drugs in the article such as Aricept, Exelon and Namenda. These drugs are cholinesterase inhibitors, ScienceBlogs Dr. Gott: Grim diagnosis for patient - Jun 29, 2008 She was diagnosed as having dementia and placed on Aricept, Namenda and Zoloft. She has since been removed from these medications because they were not Northwest Herald, New Alzheimer’s Drug Shows Promise But Falls Short of Goal - Jun 23, 2008 They include Pfizer's Aricept, Shire Ltd.'s Razadyne, Novartis AG's Exelon and Forest Laboratories Inc.'s Namenda. Other drug makers in the pursuit with HealthNews, Strong Phase III data for Forest's anti-MRSA antibiotic - Jun 20, 2008 ...and Alzheimer’s drug Namenda (memantine) will have in four-five years’ time but Forest feels its pipeline is strong enough to reduce the damage. Pharma Times (subscription), Lundbeck Maintaining Presence in Alzheimer's Disease Market ... - Jun 18, 2008 ...acquired European marketing rights to Myriad Genetics' Flurizan in May of 2008 in a timely move as its own Namenda/Ebixa faces patent expiry in 2014. Trading Markets (press release), It’s Not Alzheimer’s—He’s Just Getting Older, Right? - Jun 11, 2008 ...(Ask a dementia specialist about the FDA approved medications: Aricept, Exelon, Razadyne and Namenda.) After the neurologist treated the dementia and then North Country Gazette, Garden State Business Briefs - Jun 16, 2008 The Alzheimer's treatment market is led by four drugs: Pfizer's Aricept, Forest Laboratories' Namenda, Razadyne from Johnson & Johnson and Shire, The Star-Ledger - NJ.com, 'When it's time, it's time' - Jun 13, 2008 He is taking the medications Aricept and Namenda. They help with the symptoms of Alzheimer's, slowing the decline and helping with cognitive functions. Charleston Post Courier, America's Frightening Alzheimer's Epidemic - May 16, 2008 There's no cure, and no certain evidence that the current medications -- Aricept, Exelon, Razadyne and Namenda -- which are said to slow the course of the AlterNet, Research and Markets: New Report Gives Insight Into the Latest ... - May 29, 2008 M1 Receptor Agonist (TorreyPines) NMDA Antagonists - Namenda / Axura / Ebixa (memantine; Forest / Merz / Lundbeck / Daiichi-Sankyo) - Dimebon (dimebolin PR-Inside.com (Pressemitteilung), Myriad Genetics Selects Lundbeck as European Partner for Flurizan - May 22, 2008 Their marketed drugs include Cipralex® (marketed as Lexapro® in the US) for major depressive disorders, Ebixa® (marketed as Namenda® in the US) for moderate CNNMoney.com Myriad Making Good Deals - May 23, 2008 ...since it has the European rights to the Alzheimer's drug that Forest Laboratories (Nasdaq: FRX) markets as Namenda in the US In short, while the deal Motley Fool Thursday's Winners & Losers: Salesforce.com - May 22, 2008 Lundbeck, which markets the second most prescribed Alzheimer's drug in Europe, Ebixa (called Namenda in the US), will pay Myriad $100 million upfront for TheStreet.com Ironwood Pharmaceuticals and Forest Laboratories Announce ... - May 21, 2008 Namenda(R) (memantine HCl), an N-methyl-D-aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; FOXBusiness Forest ends promotion of Daiichi hypertension drug - May 13, 2008 The company is trying to build up its product line before its top two products -- the Lexapro anti-depressant and Namenda Alzheimer's treatment -- lose US Reuters Positive Results Of Clinical Studies For Aclidinium Bromide, A ... - May 21, 2008 Namenda(R) (memantine HCl), an N-methyl-D-aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Medical News Today (press release), My Father’s Odd Behaviors Don’t Mean He Has Alzheimer’s--He’s Just ... - May 17, 2008 ...(Ask a Dementia Specialist about the FDA approved medications: Aricept, Exelon, Razadyne and Namenda.) After the neurologist treated the dementia and then EVLiving Neurobiological Technologies, Inc. Presents Dosing Rationale for ... - May 14, 2008 NTI also has the right to receive royalty payments from sales of Namenda(R) (memantine HCL), an approved drug marketed for Alzheimer's disease, Earthtimes (press release), Senate thinking of ways to help Alzheimer's patients - May 14, 2008 Memantine, also known by its brand name Namenda®, is approved for use in moderate to severe forms of the disease. Photo of Alzheimer's disease research lab. Food Consumer, Alzheimer's Disease Brings Burdens to Patients and Their Families - May 12, 2008 Greer and Volters use a dual drug therapy with an inhibitor such as Aricept along with Namenda, a drug that helps the brain work naturally. RedOrbit, Neurobiological Technologies Sets Date for Third Quarter Financial ... - May 8, 2008 NTI also has the right to receive royalty payments from sales of Namenda(R) (memantine HCL), an approved drug marketed for Alzheimer's disease, Earthtimes (press release), Q3 2008 Myriad Genetics Earnings Conference Call - Final - May 20, 2008 If the global study were to hit on both end points, then we would have discussions with the FDA, because as you're aware, Namenda was approved with one of Insurance News Net (press release), Alzheimer's Drug Could Help Migraine Sufferers - Apr 21, 2008 To control this wave of activity, researchers tried an Alzheimer's medication called Namenda. "What we found is that it actually influences cortical KDKA, Forest Labs' Race Against the Clock - Apr 16, 2008 Revenue for the fourth quarter increased 12%, with sales of depression drug Lexapro growing 9% and Alzheimer's drug Namenda gaining 26% year over year. Motley Fool Dark Forest - Apr 15, 2008 Sales of Namenda climbed 26.0%, to $179.7 million. Forest is projecting $60 million in sales of its new hypertension treatment, Bystolic. Forbes, UPDATE 1-Forest profit beats, but outlook sluggish - Apr 15, 2008 Sales of Alzheimer's treatment Namenda climbed 26 percent to $179.7 million. The New York-based company projected fiscal-year earnings of $3.10 to $3.20 per Reuters Forest Labs Posts Profit - Apr 15, 2008 Sales of Forest Labs' two biggest-selling drugs - Lexapro for depression and Namenda for Alzheimer's and dementia - climbed 9% and 26%, respectively. Wall Street Journal Forest Labs Guides for 2009 Below Street - Apr 15, 2008 Forest expects sales of the depression treatment Lexapro to grow about 4 percent to $2.4 billion while sales of the Alzheimer's drug Namenda rise 13 percent Houston Chronicle, Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter ... - Apr 15, 2008 Sales of Namenda(R), an NMDA receptor antagonist for the treatment of moderate and severe Alzheimer's disease, totaled $226331000 in the quarter, PR Newswire (press release), Forest Lab Swings To Profit In Q4; Sees FY09 Results Below Street ... - Apr 15, 2008 The company's sales of Namenda, an NMDA receptor antagonist for the treatment of moderate and severe Alzheimer's disease, reached $226.33 million, RTT News, Forest Laboratories "hold," target price reduced - newratings.com - Apr 17, 2008 ...recover the potential decline in revenues in 2012-2014, after the patent expiry of Namenda and Lexapro, which account for 89% of the company's revenues. newratings.com, Retirement Strategies Dykstra's DITM Call: Forest Labs - Apr 17, 2008 Its two biggest drugs are anti-depressant Lexapro and Namenda, which is used to treat Alzheimer's and dementia. Forest Labs' balance sheet is pristine with TheStreet.com Forest Laboratories Swings to 4Q Profit - Apr 15, 2008 Sales of depression treatment Lexapro rose 9 percent to $577.2 million, while sales of the Alzheimer's disease drug Namenda rose 26 percent to $226.3 Houston Chronicle, Heavyweights Fall Hard - Apr 1, 2008 Lower ad outlays for Namenda were largely responsible for Forest's drop from third to 6th, while a cut in spending for Rozerem contributed to Takeda Medical Marketing and Media, Endo Announces Executive Appointment - Apr 11, 2008 He oversaw all clinical development programs at Forest including the development of Lexapro®, an SSRI antidepressant, Namenda®, an NMDA receptor antagonist CNNMoney.com TO THE POINT - Apr 15, 2008 Forest Laboratories (FRX) cited sales of depression treatment Lexapro that rose 9% to $577.2 mil, as well as sales of Alzheimer's drug Namenda that jumped Investor's Business Daily (subscription) Forest Labs Reports Q4 Profit; Provides Cautious Forecast - Apr 15, 2008 Sales of its Alzheimer's drug Namenda jumped 26% to $179.7 million. For the fiscal 2009, the company expects that reported earnings would be in a range of RTT News, Autism 5K raises about $120000 - Apr 14, 2008 We're already seeing results," Bierly said, adding that more specifically, Namenda, a drug that has recently been researched, helped improve her son's The Daily Collegian Online, Pinning High Hopes on Amyloid for Alzheimer - Apr 11, 2008 Another approved therapy in Alzheimer's disease is memantine, sold as Namenda by Forest Pharmaceuticals Inc. for more severe Alzheimer's also is aimed at BioWorld Online, Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal ... - Apr 7, 2008 Namenda(R) (memantine HCl), an N-methyl-D-aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Earthtimes, US Stocks Advance, Led by Shares of Banks, Energy Producers - Apr 15, 2008 Forest boosted spending to develop new products as Lexapro and the Alzheimer's drug Namenda, which together account for 80 percent of revenue, Bloomberg When a Mind Begins to Disappear: A Young Family’s Journey to the ... - Apr 11, 2008 Medicare pays for some of Jim's Alzheimer's medications --such as Exelon and Namenda-- as well as the antidepressant Prozac. "But still," Michelle says, Atlanta Journal Constitution, Brand Names/Synonyms: Namenda is also known by the following brand names and/or synonymsCHEMBANK733; D 145; D-145; DMAA; DRG 0267; DRG-0267; Ebixa; M183; M9292; MEMANTINE HYDROCHLORIDE; Memantina; Memantina [Inn-Spanish]; Memantine; Memantine Hydrochloride; Memantine [Inn]; Memantinum [Inn-Latin]; Namenda Drug Category: Namenda is categorized under the following by the FDA: Dopamine Agents; Antiparkinson Agents; Antidyskinetics; Excitatory Amino Acid Antagonists; Central Nervous System Agents; ATC:N06DX01 Dosage Forms: TABLET Absorption: Well absorbed orally, peak plasma concentrations are reached in 3-7 hours Interactions: -->Interactions for Memantine: N-methyl-D-aspartate (NMDA) antagonists: The combined use of NAMENDA with other NMDA antagonists (amantadine, ketamine, and dextromethorphan) has not been systematically evaluated and such use should be approached with caution. Effects of NAMENDA on substrates of microsomal enzymes: In vitro studies conducted with marker substrates of CYP450 enzymes (CYP1A2, -2A6, -2C9, -2D6, -2E1, -3A4) showed minimal inhibition of these enzymes by memantine. In addition, in vitro studies indicate that at concentrations exceeding those associated with efficacy, memantine does not induce the cytochrome P450 isozymes CYP1A2, CYP2C9, CYP2E1 and CYP3A4/5. No pharmacokinetic interactions with drugs metabolized by these enzymes are expected. Effects of inhibitors and/or substrates of microsomal enzymes on NAMENDA: Memantine is predominantly renally eliminated, and drugs that are substrates and/or inhibitors of the CYP450 system are not expected to alter the metabolism of memantine. Acetylcholinesterase (AChE) inhibitors: Coadministration of NAMENDA with the AChE inhibitor donepezil HCl did not affect the pharmacokinetics of either compound. In a 24-week controlled clinical study in patients with moderate to severe Alzheimerís disease, the adverse event profile observed with a combination of memantine and donepezil was similar to that of donepezil alone. Drugs eliminated via renal mechanisms: Because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. However, coadministration of NAMENDA and HCTZ/TA did not affect the bioavailability of either memantine or TA, and the bioavailability of HCTZ decreased by 20%. In addition, coadministration of memantine with the antihyperglycemic drug GlucovanceÒ (glyburide and metformin HCl) did not affect the pharmacokinetics of memantine, metformin and glyburide. Furthermore, memantine did not modify the serum glucose lowering effect of GlucovanceÒ. Drugs that make the urine alkaline: The clearance of memantine was reduced by about 80% under alkaline urine conditions at pH 8. Therefore, alterations of urine pH towards the alkaline condition may lead to an accumulation of the drug with a possible increase in adverse effects. Urine pH is altered by diet, drugs (e.g. carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g. renal tubular acidosis or severe infections of the urinary tract). Hence, memantine should be used with caution under these conditions. Chemical IUPAC Name: 3,5-dimethyladamantan-1-amine : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |